All In Biotech

Drug Trial Radar · NCT00819585

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

A 24-week, Dose-ranging, Multicenter, Double-blind, Double-dummy, Active-controlled Core Study to Evaluate Canakinumab for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy and a 24-week Open-label, Multicenter Extension Study to Assess Safety, Tolerability and Efficacy of Canakinumab in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare

Last checked: Nov 20, 2026Latest source record: Jul 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

432

Actual

Start

Dec 2008

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy. The core study was followed by a 24-week open-label, multicenter extension study to assess the safety, tolerability, and efficacy of canakinumab in patients with gout who were given canakinumab at the time of gout flare.

Conditions

  • Gout

Interventions

  • CanakinumabDrug

    Canakinumab was supplied in glass vials as a lyophilized powder.

  • ColchicineDrug

    0.5 mg capsule orally once daily for 16 weeks.

  • AllopurinolDrug

    100-300 mg orally once daily for 24 weeks.

  • Placebo Matching CanakinumabDrug

    Subcutaneous injection.

  • Placebo Matching ColchicineDrug

    Capsule orally once daily for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Study: Mean Number of Gout Flares Per ParticipantTime frame: Baseline of the core study to Week 16

Locations

89 sites in 18 countries. Site status is shown where the registry gives one.

  • Talbert Medical Group

    Huntington Beach, California

  • San Diego Arthritis & Osteoporosis Medical clinic

    San Diego, California

  • Health Awareness

    Jupiter, Florida

  • East-West Medical Research institute

    Honolulu, Hawaii

  • Pinnacle Medical Research

    Overland Park, Kansas

  • Cotton O'Neil Clinical Research Institute

    Topeka, Kansas

  • Dolby Research, LLC

    Baton Rouge, Louisiana

  • The Family Doctors

    Shreveport, Louisiana

  • Shores Rheumatology

    Saint Clair Shores, Michigan

  • Heartland Clinical Research, Inc.

    Omaha, Nebraska

  • NM Clinical Research & Osteoporosis Ct.

    Albuquerque, New Mexico

  • Rochester clinical Research

    Rochester, New York

  • Health Research of Oklahoma, PLLC

    Oklahoma City, Oklahoma

  • Castlerock Clinical Research Consultants, LLC

    Tulsa, Oklahoma

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Columbia Clinical Research

    Columbia, South Carolina

  • Upstate Pharmaceutical Research

    Greenville, South Carolina

  • MultiSpecialty Clinical Research

    Johnson City, Tennessee

  • iMED Internal medicine, PA

    San Antonio, Texas

  • Novartis Investigative site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative site

    Rosario, Argentina

  • Novartis Investigative Site

    Gozée, Belgium

  • Novartis Investigative site

    Oostham, Belgium

  • Novartis Investigative Site

    Bacaramanga, Colombia

  • Novartis Investigative Site

    Barranquilla, Colombia

  • Novartis Investigative Site

    Bogotá, Colombia

  • Fundación Cardiovascular de Colombia

    Florida Blanca, Colombia

  • Novartis Investigative site

    Havířov, Czechia

  • Novartis Investigative site

    Ostrava, Czechia

  • Novartis Investigative site

    Pardubice, Czechia

  • Novartis Investigative site

    Uherské Hradiště, Czechia

  • Novartis Investigative site

    Zlín, Czechia

  • Novartis Investigative Site

    Bautzen, Germany

  • Novartis Investigative Site

    Chemnitz, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Georgensgmünd, Germany

  • Novartis Investigative Site

    Göttingen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.